Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.46 |
| ▸ | F11 | P03951 | 6/20 | 0.46 |
| ▸ | F7 | P08709 | 6/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11024163 | 0.91 | F10 (0.47) | F10F11F7ARNPC1 | |
| SCHEMBL11027217 | 0.90 | SMYD3 (0.41) | F10F11F7ARNPC1 | |
| SCHEMBL11024600 | 0.89 | F11 (0.45) | F10F11F7ARSMN1; SMN2 | |
| SCHEMBL11025078 | 0.89 | SMN1; SMN2 (0.48) | F10F11F7NPC1RAB9A | |
| SCHEMBL11024121 | 0.85 | TP53 (0.44) | F10F11F7ARKDM4E | |
| SCHEMBL11027270 | 0.84 | CACNA1F (0.46) | F10F11F7ARSMN1; SMN2 | |
| SCHEMBL11026020 | 0.83 | AR (0.40) | F10F11F7ARNPC1 | |
| SCHEMBL11023402 | 0.83 | F11 (0.45) | F10F11F7ARAKR1B1 | |
| SCHEMBL11025597 | 0.80 | F11 (0.42) | F10F11F7ARCASR | |
| SCHEMBL11024947 | 0.79 | TP53 (0.41) | F10F11F7SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | F10 2432/4885F11 2989/4885F7 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.